Galmed Pharmaceuticals (GLMD) to Release Earnings on Wednesday

Galmed Pharmaceuticals (NASDAQ:GLMD) will likely be issuing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $1.2990 million for the quarter.

Galmed Pharmaceuticals Stock Up 1.3%

Shares of GLMD opened at $0.59 on Wednesday. The business’s 50 day moving average price is $0.66 and its 200-day moving average price is $1.00. Galmed Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $2.68. The stock has a market cap of $3.22 million, a P/E ratio of -1.84 and a beta of 0.40.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 3.05% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is currently owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.